AzurRx Biopharma, Inc. Appoints Daniel Schneiderman as Chief Financial Officer
January 03, 2020 at 01:00 pm
Share
AzurRx BioPharma, Inc. announced that Daniel Schneiderman has been appointed to serve as the Company’s Chief Financial Officer effective January 2, 2020. Mr. Schneiderman, who has over 17 years of healthcare and finance experience, most recently served as Chief Financial Officer for Biophytis, SA (through its U.S. subsidiary Biophytis, Inc.) (Euronext Growth Paris: ALBPS) from November 2018 through December 2019. Previously, Mr. Schneiderman served as the Vice President, Finance, Controller and Corporate Secretary for MetaStat, Inc. from February 2012 through October 2018. Mr. Schneiderman’s early career included a number of investment banking positions where he focused on private and public small capitalization companies mainly in the healthcare and life sciences sectors. Mr. Schneiderman was Vice President of Investment Banking for Burnham Hill Partners LLC, where he worked from 2008 to 2012. From 2004 through 2008, Mr. Schneiderman was Vice President of Investment Banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, Mr. Schneiderman worked at H.C. Wainwright & Co., Inc. in 2004 as an investment banking analyst. Mr. Schneiderman earned a bachelor’s degree in economics from Tulane University. Mr. Schneiderrman replaces Maged Shenouda, who left the Company on November 30, 2019 to pursue other career opportunities.
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The Company also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
ENTERO THERAPEUTICS, INC. 
